Abstract
There is a growing interest focusing on the inflammatory response caused by essential hypertension. Inflammatory mechanisms play an important role in the pathogenesis and progression of cardiovascular disease. Recent studies have shown that tissue expression and plasma concentrations of several inflammatory markers and mediators are associated with increased risk of hypertension. These molecules include C-reactive protein, adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and chemokines. The evaluation of these markers may influence the specific pharmacologic responses and the clinical outcome of the patients with essential hypertension. Moreover, therapeutic approaches targeted to lower blood pressure and suppress inflammatory response may have additional clinical benefits. However, further randomized studies are required to determine the potential favorable effects of suppression of inflammation in the management of arterial hypertension.
Keywords: Hypertension, inflammation, markers, therapeutic approaches
Current Vascular Pharmacology
Title: Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Volume: 8 Issue: 4
Author(s): Elli Stefanadi, Dimitris Tousoulis, Emmanuel S. Androulakis, Nikolaos Papageorgiou, Marietta Charakida, Gerasimos Siasos, Costas Tsioufis and Christodoulos Stefanadis
Affiliation:
Keywords: Hypertension, inflammation, markers, therapeutic approaches
Abstract: There is a growing interest focusing on the inflammatory response caused by essential hypertension. Inflammatory mechanisms play an important role in the pathogenesis and progression of cardiovascular disease. Recent studies have shown that tissue expression and plasma concentrations of several inflammatory markers and mediators are associated with increased risk of hypertension. These molecules include C-reactive protein, adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and chemokines. The evaluation of these markers may influence the specific pharmacologic responses and the clinical outcome of the patients with essential hypertension. Moreover, therapeutic approaches targeted to lower blood pressure and suppress inflammatory response may have additional clinical benefits. However, further randomized studies are required to determine the potential favorable effects of suppression of inflammation in the management of arterial hypertension.
Export Options
About this article
Cite this article as:
Stefanadi Elli, Tousoulis Dimitris, S. Androulakis Emmanuel, Papageorgiou Nikolaos, Charakida Marietta, Siasos Gerasimos, Tsioufis Costas and Stefanadis Christodoulos, Inflammatory Markers in Essential Hypertension: Potential Clinical Implications, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330870
DOI https://dx.doi.org/10.2174/157016110791330870 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-activity Relationship of Chemical Penetration Enhan-cers in Transdermal Drug Delivery
Current Medicinal Chemistry Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Diuretic-Associated Electrolyte Disorders in the Elderly: Risk Factors, Impact, Management and Prevention
Current Drug Safety Microdialysis in Drug Discovery
Current Drug Discovery Technologies Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Pathogenesis-Oriented Targets for Adjunctive Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic Syndrome, its Pathophysiology and the Role of Melatonin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nanosystems for Skin Delivery: From Drugs to Cosmetics
Current Drug Metabolism Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets An NMR Metabolomic Study in the Old Order Amish to Study Increased Dietary Salt Associated with Elevation of Organic Osmolytes Detected in Urine
Current Metabolomics Interstitial Lung Disease in Sjogrens Syndrome
Current Rheumatology Reviews Bioinformatics Analysis of Functional Protein Sequences Reveals a Role for Tumor Necrosis Factor-α and Nitric Oxide in Insulin Resistance Syndrome
Current Nutrition & Food Science The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Benign Prostatic Hyperplasia and Clinical Prostate Cancer - Two New Components of the Metabolic Syndrome
Current Hypertension Reviews The Podocyte: a Potential Therapeutic Target in Diabetic Nephropathy?
Current Pharmaceutical Design Diabetes as a Negative Risk Factor for Abdominal Aortic Aneurysm – Does the Disease Aetiology or the Treatment Provide the Mechanism of Protection?
Current Vascular Pharmacology